Anti-Human GM-CSF (Clone 3209)

Purified Recombinant Human GM-CSF (Accession # P04141)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Human GM-CSF bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human GM-CSF (at 0.5 ng/ml) is 0.3 - 0.5 µg/ml.
Immunocytochemistry: Suitable for use at concentration of 8-25 µg/mL.

Clone 3209 recognizes an epitope on human GM-CSF. In direct ELISAs, this antibody exhibits less than 15% cross-reactivity with rmGM-CSF.

Granulocyte-Macrophage Colony Stimulating Factor is a 22 kD, pleiotropic cytokine that is a white blood cell growth factor. It controls the production and function of blood cells by stimulating stem cells to produce granulocytes and monocytes. GM-CSF differs from G-CSF in that it affects more cell types including macrophages and eosinophils. Moreover, GM-CSF is part of the immune/inflammatory cascade, a process crucial for fighting infection. Interestingly, GM-CSF expression may have pathological implications. Autocrine expression of GM-CSF in myeloid leukemia cells is suspected to play a role in neoplasia, the formation of a new and abnormal growth of tissue. Additionally, GM-CSF expression has also been documented in certain solid tumors. There have also been reports of GM-CSF in synovial fluid from patients with arthritis suggesting that GM-CSF may play a role in tissue damage associated with the inflammatory process. Blocking GM-CSF is thought to have therapeutic potential by reducing inflammation. Some drugs are currently being developed to block GM-CSF.

1. Parker, MW. et al. (2008) Cell 134: 496
2. Whitsett, JA. et al. (2002) Annual Review of Physiology 64: 775